ASAnuradhaa Subramanian

Anuradhaa Subramanian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anuradhaa Subramanian has a total of 401 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Obstructive sleep apnoea and cardiovascular risk in atrial fibrillation: a health system-based cohort study

    by Jingya Wang, Christina Antza, Xian Shen, Tiffany Gooden, Abd Tahrani, Deirdre A Lane, Anuradhaa Subramanian, Krishna Gokhale, Nicola Jaime Adderley, Rajendra Surenthirakumaran, et al.

  • Open Access

    Autoimmune diseases and risk of adverse pregnancy outcomes: a population-based cohort study of five million pregnancies in the UK

    by Megha Singh, Anuradhaa Subramanian, Steven Wambua, Neil Cockburn, Stephanie J Hanley, Siang Ing Lee, Arturo Gonzalez-Izquierdo, Mairead Black, John A Reynolds, Francesca L Crowe, et al.

    Background: With an increasing trend in the prevalence of maternal autoimmune diseases in pregnancy, there is need for evidence on the association between autoimmune diseases and pregnancy outcomes. Methods: This population-based cohort study used data on pregnancies from primary care practices that contributed to the UK Clinical Practice Research Datalink (CPRD) database (Gold and Aurum) between 2000 and 2022, linked to Hospital Episode Statistics (HES). Modified Poisson regression with robust standard errors estimated adjusted relative risks (aRR) and 95% confidence intervals (95% CI) assessing the association between 17 autoimmune diseases and 12 pregnancy outcomes, selected following literature review and expert consultation. Models were adjusted for demographic and comorbidity variables. Findings were evaluated using the Benjamini–Yekutieli procedure to control for multiple testing across autoimmune disease–outcome associations. Results: A total of 5,239,383 pregnancies from the CPRD pregnancy register and 2,485,366 births recorded in HES maternity data met the eligibility criteria. Women with autoimmune diseases had an increased risk across all pregnancy outcomes examined. Among antenatal outcomes, markedly elevated risks were observed for hyperemesis gravidarum in Addison’s disease (aRR 3.72, 95% CI 2.48–5.59), miscarriage in Sjögren’s syndrome (1.66, 1.02–2.70), gestational hypertension in type 1 diabetes mellitus (T1DM; 2.95, 2.77–3.15), pre-eclampsia/eclampsia in T1DM (3.56, 3.32–3.82), and gestational diabetes mellitus in Graves’ disease (1.37, 1.21–1.54). For obstetric outcomes, increased risks were observed for caesarean birth in inflammatory bowel disease (IBD; 1.27, 1.22–1.31), small for gestational age in systemic lupus erythematosus (SLE; 2.45, 1.65–3.62), preterm birth in rheumatoid arthritis (1.53, 1.33–1.76), and stillbirth in SLE (1.82, 1.12–1.84). Perinatal mental health outcomes were more common across several autoimmune diseases, with particularly high risks in myasthenia gravis (anxiety 3.05, 1.89–4.92; depression 1.77, 1.37–2.28), SLE (anxiety 2.11, 1.67–2.67; depression 1.36, 1.22–1.53), and multiple sclerosis (anxiety 1.76, 1.38–2.23; depression 1.94, 1.77–2.12). Inverse associations were observed for hyperemesis gravidarum in systemic sclerosis, SLE, and myasthenia gravis, and for hypertensive disorders of pregnancy in multiple sclerosis. After Benjamini–Yekutieli correction for multiple testing, the number of statistically significant associations was reduced, with a core set of robust associations persisting across selected autoimmune diseases particularly, T1DM, SLE, Graves’ disease, IBD and key pregnancy outcomes. Conclusions: Autoimmune diseases were associated with increased risks across a wide range of adverse pregnancy outcomes, with marked heterogeneity between individual conditions. This study provides adjusted relative risks across multiple domains of pregnancy outcomes including antenatal (e.g. miscarriage, hyperemesis gravidarum, gestational hypertension, pre-eclampsia, gestational diabetes), obstetric (e.g. preterm birth, caesarean birth, small for gestational age, stillbirth), and perinatal mental health outcomes (anxiety and depression), for both common and less frequently studied autoimmune diseases. The findings highlight the importance of disease-specific evaluation of pregnancy risks.


  • Open Access

    Gender and contemporary risk of adverse events in atrial fibrillation

    by Asgher Champsi, Alastair R Mobley, Anuradhaa Subramanian, Krishnarajah Nirantharakumar, Xiaoxia Wang, David Shukla, Karina V Bunting, Inge Molgaard, Jeremy Dwight, Ruben Casado Arroyo, et al.

    The role of gender in decision-making for oral anticoagulation in patients with atrial fibrillation (AF) remains controversial. The population cohort study used electronic healthcare records of 16 587 749 patients from UK primary care (2005–2020). Primary (composite of all-cause mortality, ischaemic stroke, or arterial thromboembolism) and secondary outcomes were analysed using Cox hazard ratios (HR), adjusted for age, socioeconomic status, and comorbidities. 78 852 patients were included with AF, aged 40–75 years, no prior stroke, and no prescription of oral anticoagulants. 28 590 (36.3%) were women, and 50 262 (63.7%) men. Median age was 65.7 years (interquartile range 58.5–70.9), with women being older and having other differences in comorbidities. During a total follow-up of 431 086 patient-years, women had a lower adjusted primary outcome rate with HR 0.89 vs. men (95% confidence interval [CI] 0.87–0.92; P < .001) and HR 0.87 after censoring for oral anticoagulation (95% CI 0.83–0.91; P < .001). This was driven by lower mortality in women (HR 0.86, 95% CI 0.83–0.89; P < .001). No difference was identified between women and men for the secondary outcomes of ischaemic stroke or arterial thromboembolism (adjusted HR 1.00, 95% CI 0.94–1.07; P = .87), any stroke or any thromboembolism (adjusted HR 1.02, 95% CI 0.96–1.07; P = .58), and incident vascular dementia (adjusted HR 1.13, 95% CI 0.97–1.32; P = .11). Clinical risk scores were only modest predictors of outcomes, with CHA2DS2-VA (ignoring gender) superior to CHA2DS2-VASc for primary outcomes in this population (receiver operating characteristic curve area 0.651 vs. 0.639; P < .001) and no interaction with gender (P = .45). Removal of gender from clinical risk scoring could simplify the approach to which patients with AF should be offered oral anticoagulation. The impact of gender on adverse events in patients with atrial fibrillation (AF) based on a population cohort study using electronic healthcare records from UK primary care (2005–20).


  • Open Access

    Pregnancy complications and autoimmune diseases in women: systematic review and meta-analysis

    by Megha Singh, Fathima Fazla Ahamed Fayaz, Jingya Wang, Steven Wambua, Anuradha Subramanian, John A. Reynolds, Krishnarajah Nirantharakumar, Francesca Crowe, on behalf of MuM-PreDiCT

    Background: Pregnancy complications might lead to the development of autoimmune diseases in women. This review aims to summarise studies evaluating the association between pregnancy complications and the development of autoimmune diseases in women. Methods: Medline, CINAHL, and Cochrane databases were searched up to January 2024. Nineteen pregnancy complications and 15 autoimmune conditions were included. Title, abstract, full-text screening, data extraction, and quality assessment were performed by two reviewers independently. Data were synthesised using narrative and quantitative methods. Results were presented using odds ratios (OR), relative risks (RR), incidence rate ratios (IRR), and 95% confidence intervals (CI). Results: Thirty studies were included. One study reported composite exposure to pregnancy complications had a risk of any autoimmune disease RR 3.20 (2.90–3.51) compared to women without pregnancy complications. Women with hyperemesis gravidarum had a higher risk of developing coeliac disease (n = 1) IRR 1.98 (1.27–2.94), Crohn’s disease (n = 1) IRR 1.61 (1.25–2.04), psoriasis (n = 1) IRR 1.33 (1.01–1.71), and rheumatoid arthritis (n = 2) IRR 1.35 (1.09–1.64). Miscarriage associated with subsequent diagnosis of Sjogren syndrome (n = 2) IRR 1.33 (1.06–2.81) and rheumatoid arthritis (n = 4) OR 1.11 (1.04–1.20). Gestational hypertension/preeclampsia was linked with the development of systemic sclerosis (n = 2) IRR 2.60 (1.10–4.60) and T1DM (n = 2) IRR 2.37 (2.09–2.68). Stillbirth associated with composite autoimmune conditions (n = 2) RR 5.82 (95% CI 4.87–6.81) and aIRR 1.25 (1.12–1.40). Postpartum psychosis was associated with autoimmune thyroid disease (n = 1) aIRR2.26 (1.61–2.90). Conclusions: Women with pregnancy complications subsequently had a higher risk of being diagnosed with autoimmune conditions. Whether this is due to pre-existing undiagnosed health conditions or being causally linked to pregnancy complications is not known.


  • Open Access

    Thromboembolic events and vascular dementia in patients with atrial fibrillation and low apparent stroke risk

    by Alastair R. Mobley, Anuradhaa Subramanian, Asgher Champsi, Xiaoxia Wang, Puja Myles, Paul McGreavy, Karina V. Bunting, David Shukla, Krishnarajah Nirantharakumar, Dipak Kotecha

    The prevention of thromboembolism in atrial fibrillation (AF) is typically restricted to patients with specific risk factors and ignores outcomes such as vascular dementia. This population-based cohort study used electronic healthcare records from 5,199,994 primary care patients (UK; 2005–2020). A total of 290,525 (5.6%) had a diagnosis of AF and were aged 40–75 years, of which 36,340 had no history of stroke, a low perceived risk of stroke based on clinical risk factors and no oral anticoagulant prescription. Matching was performed for age, sex and region to 117,298 controls without AF. During 5 years median follow-up (831,005 person-years), incident stroke occurred in 3.8% with AF versus 1.5% control (adjusted hazard ratio (HR) 2.06, 95% confidence interval (CI) 1.91–2.21; P < 0.001), arterial thromboembolism 0.3% versus 0.1% (HR 2.39, 95% CI 1.83–3.11; P < 0.001), and all-cause mortality 8.9% versus 5.0% (HR 1.44, 95% CI 1.38–1.50; P < 0.001). AF was associated with all-cause dementia (HR 1.17, 95% CI 1.04–1.32; P = 0.010), driven by vascular dementia (HR 1.68, 95% CI 1.33–2.12; P < 0.001) rather than Alzheimer’s disease (HR 0.85, 95% CI 0.70–1.03; P = 0.09). Death and thromboembolic outcomes, including vascular dementia, are substantially increased in patients with AF despite a lack of conventional stroke risk factors.


  • Open Access

    Detection and evaluation of signals associated with exposure to individual and combination of medications in pregnancy: a signal detection study protocol

    by Anuradhaa Subramanian, Siang Ing Lee, Sudasing Pathirannehelage Buddhika Hemali Sudasinghe, Steven Wambua, Katherine Phillips, Megha Singh, Amaya Azcoaga-Lorenzo, Neil Cockburn, Jingya Wang, Adeniyi Fagbamigbe, et al.

    Introduction Considering the high prevalence of polypharmacy in pregnant women and the knowledge gap in the risk–benefit safety profile of their often-complex treatment plan, more research is needed to optimise prescribing. In this study, we aim to detect adverse and protective effect signals of exposure to individual and pairwise combinations of medications during pregnancy. Methods and analysis Using a range of real-world data sources from the UK, we aim to conduct a pharmacovigilance study to assess the safety of medications prescribed during the preconception period (3 months prior to conception) and first trimester of pregnancy. Women aged between 15 and 49 years with a record of pregnancy within the Clinical Practice Research Datalink (CPRD) Pregnancy Register, the Welsh Secure Anonymised Information Linkage (SAIL), the Scottish Morbidity Record (SMR) data sets and the Northern Ireland Maternity System (NIMATS) will be included. A series of case control studies will be conducted to estimate measures of disproportionality, detecting signals of association between a range of pregnancy outcomes and exposure to individual and combinations of medications. A multidisciplinary expert team will be invited to a signal detection workshop. By employing a structured framework, signals will be transparently assessed by each member of the team using a questionnaire appraising the signals on aspects of temporality, selection, time and measurement-related biases and confounding by underlying disease or comedications. Through group discussion, the expert team will reach consensus on each of the medication exposure–outcome signal, thereby excluding spurious signals, leaving signals suggestive of causal associations for further evaluation. Ethics and dissemination Ethical approval has been obtained from the Independent Scientific Advisory Committee, SAIL Information Governance Review Panel, University of St. Andrews Teaching and Research Ethics Committee and Office for Research Ethics Committees Northern Ireland (ORECNI) for access and use of CPRD, SAIL, SMR and NIMATS data, respectively.

  • Open Access

    Long Covid symptoms and diagnosis in primary care: A cohort study using structured and unstructured data in The Health Improvement Network primary care database

    by Anoop D. Shah, Anuradhaa Subramanian, Jadene Lewis, Samir Dhalla, Elizabeth Ford, Shamil Haroon, Valerie Kuan, Krishnarajah Nirantharakumar

    Background: Long Covid is a widely recognised consequence of COVID-19 infection, but little is known about the burden of symptoms that patients present with in primary care, as these are typically recorded only in free text clinical notes.Aims: To compare symptoms in patients with and without a history of COVID-19, and investigate symptoms associated with a Long Covid diagnosis.Methods: We used primary care electronic health record data until the end of December 2020 from The Health Improvement Network (THIN), a Cegedim database. We included adults registered with participating practices in England, Scotland or Wales. We extracted information about 89 symptoms and ‘Long Covid’ diagnoses from free text using natural language processing. We calculated hazard ratios (adjusted for age, sex, baseline medical conditions and prior symptoms) for each symptom from 12 weeks after the COVID-19 diagnosis.Results: We compared 11,015 patients with confirmed COVID-19 and 18,098 unexposed controls. Only 20% of symptom records were coded, with 80% in free text. A wide range of symptoms were associated with COVID-19 at least 12 weeks post-infection, with strongest associations for fatigue (adjusted hazard ratio (aHR) 3.46, 95% confidence interval (CI) 2.87, 4.17), shortness of breath (aHR 2.89, 95% CI 2.48, 3.36), palpitations (aHR 2.59, 95% CI 1.86, 3.60), and phlegm (aHR 2.43, 95% CI 1.65, 3.59). However, a limited subset of symptoms were recorded within 7 days prior to a Long Covid diagnosis in more than 20% of cases: shortness of breath, chest pain, pain, fatigue, cough, and anxiety / depression.Conclusions: Numerous symptoms are reported to primary care at least 12 weeks after COVID-19 infection, but only a subset are commonly associated with a GP diagnosis of Long Covid.


  • Open Access

    Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care

    by Umer Syed, Anuradhaa Subramanian, David C. Wraith, Janet M. Lord, Kirsty McGee, Krishna Ghokale, Krishnarajah Nirantharakumar, Shamil Haroon

    Background: Some patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) go on to experience post-COVID-19 condition or long COVID. Preliminary findings have given rise to the theory that long COVID may be due in part to a deranged immune response. In this study, we assess whether there is an association between SARS-CoV-2 infection and the incidence of immune-mediated inflammatory diseases (IMIDs). Methods: Matched cohort study using primary care electronic health record data from the Clinical Practice Research Datalink Aurum database. The exposed cohort included 458,147 adults aged 18 years and older with a confirmed SARS-CoV-2 infection and no prior diagnosis of IMIDs. They were matched on age, sex, and general practice to 1,818,929 adults with no diagnosis of confirmed or suspected SARS-CoV-2 infection. The primary outcome was a composite of any of the following IMIDs: autoimmune thyroiditis, coeliac disease, inflammatory bowel disease (IBD), myasthenia gravis, pernicious anaemia, psoriasis, rheumatoid arthritis (RA), Sjogren’s syndrome, systemic lupus erythematosus (SLE), type 1 diabetes mellitus (T1DM), and vitiligo. The secondary outcomes were each of these conditions separately. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for the primary and secondary outcomes, adjusting for age, sex, ethnic group, smoking status, body mass index, relevant infections, and medications. Results: Six hundred and nighty six (0.15%) and 2230 (0.12%) patients in the exposed and unexposed cohort developed an IMID during the follow-up period over 0.29 person-years, giving a crude incidence rate of 4.59 and 3.65 per 1000 person-years, respectively. Patients in the exposed cohort had a 22% increased risk of developing an IMID, compared to the unexposed cohort (aHR 1.22, 95% CI 1.12 to 1.33). The incidence of three IMIDs was significantly associated with SARS-CoV-2 infection. These were T1DM (aHR 1.56, 1.09 to 2.23), IBD (aHR 1.36, 1.18 to 1.56), and psoriasis (1.23, 1.05 to 1.42). Conclusions: SARS-CoV-2 was associated with an increased incidence of IMIDs including T1DM, IBD and psoriasis. However, these findings could be potentially due to ascertainment bias. Further research is needed to replicate these findings in other populations and to measure autoantibody profiles in cohorts of individuals with COVID-19.


  • Blood biomarkers and biological age among patients with long COVID

    by Anuradhaa Subramanian, Krishnarajah Nirantharakumar, Janet Lord, David C. Wraith, Shamil Haroon

    Introduction: Symptom based clustering suggests that long COVID is a heterogenous condition with distinct phenotypes. We aimed to assess whether blood biomarkers and biological age differ across these phenotypes. Methods: A retrospective cohort study was done using English primary care data in the Clinical Practice Research Datalink Aurum database. We included 384,786 non-hospitalised patients with confirmed SARS-CoV-2 infection. They were classified using latent class analysis as having either a broad spectrum, respiratory, or mental health/cognitive symptoms. Blood biomarkers were extracted at 12 weeks after infection to estimate biological age (PhenoAge). Differences in biomarkers and biological age across the phenotypes and asymptomatic controls were tested using ANOVA. Chronological age was subtracted from biological age to measure excess ageing. The association between long COVID phenotypes and excess ageing was assessed using multivariable linear regression. Results: Patients from the respiratory phenotype (n=2866) were distinct and reported lower levels of albumin, and higher levels of creatinine, glucose, C-reactive protein, erythrocyte sedimentation rate, and white cell count. Patients within the broad spectrum and respiratory phenotypes were on average 0.67 and 2.25 years biologically older than their chronological age, while patients within the mental health phenotype were 0.11 years younger (p<0.001). After adjusting for confounders, this remained statistically significant among patients within the broad symptom spectrum cluster (β: 0.50, 95% CI 0.15-0.84; p=0.005). Conclusion: Long COVID phenotypes correspond to differences in blood biomarkers and biological ageing.

  • Open Access

    Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

    by Dorte Vistisen, Bendix Carstensen, Patorno Elisabetta, Stefanie Lanzinger, Elise Chia-Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H.-H. Sheu, Cheli Melzer-Cohen, Reinhard W. Holl, et al.

    Background: Studies that have reported lower risk for cardiovascular outcomes in users of Sodium–Glucose Cotransporter-2 Inhibitors (SGLT-2i) are limited by residual cofounding and lack of information on prior cardiovascular disease (CVD). This study compared risk of cardiovascular events in patients within routine care settings in Europe and Asia with type 2 diabetes (T2D) initiating empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP-4i) stratified by pre-existing CVD and history of heart failure (HF). Methods and results: Adults initiating empagliflozin and DPP-4i in 2014–2018/19 from 11 countries in Europe and Asia were compared using propensity score matching and Cox proportional hazards regression to assess differences in rates of primary outcomes: hospitalisation for heart failure (HHF), myocardial infarction (MI), stroke; and secondary outcomes: cardiovascular mortality (CVM), coronary revascularisation procedure, composite outcome including HHF or CVM, and 3-point major adverse cardiovascular events (MACE: MI, stroke and CVM). Country-specific results were meta-analysed and pooled hazard ratios (HR) with 95% confidence intervals (CI) from random-effects models are presented. In total, 85,244 empagliflozin/DPP4i PS-matched patient pairs were included with overall mean follow-up of 0.7 years. Among those with pre-existing CVD, lower risk was observed for HHF (HR 0.74; 95% CI 0.64–0.86), CVM (HR 0.55; 95% CI 0.38–0.80), HHF or CVM (HR 0.57; 95% CI 0.48–0.67) and stroke (HR 0.79; 95% CI 0.67–0.94) in patients initiating empagliflozin vs DPP-4i. Similar patterns were observed among patients without pre-existing CVD and those with and without pre-existing HF. Conclusion: These results from diverse patient populations in routine care settings across Europe and Asia demonstrate that initiation of empagliflozin compared to DPP-4i results in favourable cardioprotective effects regardless of pre-existing CVD or HF status.